Clinical Trial Update: Study of LP-184 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Lantern Pharma's LP-184 is being studied in a phase 1/2 trial for advanced and metastatic solid tumors, with indications including glioblastoma, triple-negative…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• LP-184 (LP-184)

Snippet

Sponsor: Lantern Pharma Inc. | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING